AzurRx BioPharma Inc.

0.8698+0.0856+10.92%Vol 21.78M1Y Perf 26.08%
Apr 20th, 2021 16:00 DELAYED
BID0.8300 ASK0.8400
Open0.7752 Previous Close0.7842
Pre-Market- After-Market-
 - -  - -%
Target Price
3.63 
Analyst Rating
Strong Buy 1.00
Potential %
317.34 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap64.75M 
Earnings Rating
Neutral
Price Range Ratio 52W %
14.52 
Earnings Date
21st May 2021

Today's Price Range

0.77310.9898

52W Range

0.57092.63

5 Year PE Ratio Range

-6.40-2.30

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
2.33%
1 Month
-37.42%
3 Months
-29.85%
6 Months
5.43%
1 Year
26.08%
3 Years
-74.72%
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
AZRX0.86980.085610.92
AAPL133.11-1.7300-1.28
GOOG2 293.63-8.7700-0.38
MSFT258.26-0.4800-0.19
XOM55.29-1.1900-2.11
WFC42.54-1.3400-3.05
JNJ166.483.79002.33
FB302.650.41000.14
GE13.06-0.4000-2.97
JPM149.27-3.3800-2.21
Earnings HistoryEstimateReportedSurprise %
Q03 2020-0.12-0.47-291.67
Q02 2020-0.09-0.17-88.89
Q01 2020-0.11-0.20-81.82
Q03 2019-0.15-0.17-13.33
Q02 2019-0.22-0.25-13.64
Q01 2019-0.18-0.26-44.44
Q01 2018-0.18-0.29-61.11
Q03 2017-0.15-0.28-86.67
Earnings Per EndEstimateRevision %Trend
12/2020 FY-0.870.00-
3/2021 QR-0.0820.00Positive
6/2021 QR-0.0633.33Positive
12/2021 FY-0.2730.77Positive
Next Report Date21st May 2021
Estimated EPS Next Report-0.08
Estimates Count3
EPS Growth Next 5 Years %-
Volume Overview
Volume21.78M
Shares Outstanding74.44M
Trades Count26.63K
Dollar Volume3.10M
Avg. Volume8.76M
Avg. Weekly Volume5.24M
Avg. Monthly Volume4.49M
Avg. Quarterly Volume9.33M

AzurRx BioPharma Inc. (NASDAQ: AZRX) stock closed at 0.8698 per share at the end of the most recent trading day (a 10.92% change compared to the prior day closing price) with a volume of 21.93M shares and market capitalization of 64.75M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 10 people. AzurRx BioPharma Inc. CEO is James Sapirstein.

The one-year performance of AzurRx BioPharma Inc. stock is 26.08%, while year-to-date (YTD) performance is -10.33%. AZRX stock has a five-year performance of %. Its 52-week range is between 0.5709 and 2.63, which gives AZRX stock a 52-week price range ratio of 14.52%

AzurRx BioPharma Inc. currently has a PE ratio of -0.70, a price-to-book (PB) ratio of 6.76, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -369.04%, a ROC of -191.85% and a ROE of -3 497.72%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from AzurRx BioPharma Inc., there were 0 positive earnings surprise and 4 negative earnings surprise. The company has EPS estimate of $-0.08 for the next earnings report. AzurRx BioPharma Inc.’s next earnings report date is 21st May 2021.

The consensus rating of Wall Street analysts for AzurRx BioPharma Inc. is Strong Buy (1), with a target price of $3.63, which is +317.34% compared to the current price. The earnings rating for AzurRx BioPharma Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

AzurRx BioPharma Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

AzurRx BioPharma Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 24.88, ATR14 : 0.15, CCI20 : -87.42, Chaikin Money Flow : 0.24, MACD : -0.19, Money Flow Index : 49.73, ROC : -41.48, RSI : 38.06, STOCH (14,3) : 3.84, STOCH RSI : 0.12, UO : 41.70, Williams %R : -96.16), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of AzurRx BioPharma Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
3 (100.00 %)
3 (75.00 %)
4 (80.00 %)
Moderate Buy
0 (0.00 %)
1 (25.00 %)
1 (20.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.18
Strong Buy
1.14

AzurRx BioPharma Inc.

AzurRx BioPharma Inc is a development stage biopharmaceutical company. The company is focused on the development of recombinant proteins for the treatment of gastrointestinal diseases and microbiome-related conditions. Its lead product candidate is MS1819, a yeast-derived recombinant lipase for exocrine pancreatic insufficiency (EPI) associated with cystic fibrosis (CF) and chronic pancreatitis (CP).

CEO: James Sapirstein

Telephone: +1 646 699-7855

Address: 760 Parkside Avenue, Brooklyn 11226, NY, US

Number of employees: 10

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

67%33%

Bearish Bullish

56%44%

Bearish Bullish

55%45%

Bearish Bullish

59%41%

News

Stocktwits